P/El ratio now well over 1000, P/S ratio over 20 for a "social media" site that produces nothing. How fat is this turkey going to get? Or, rather, how much lip stick are they going to layer on this pig?
And on the revenue side Erivedge continues to pick-up steam, posting yet another 30% increase in quarter-to-quarter sales. This may increase even more once AU and EU sales start factoring in.
Well I had some cash to buy, and I have done so. To put some weight to my opinion however let me point out that Curis is now over 50 percent off of its high that it was poised at only a matter of weeks ago. Does anybody really believe that the intrinsic value of this company has declined by that much due to one phase 1 trial not being rejected, but placed on hold?? That's preposterous. It's especially so considering that this company has several trials in the works. The most pertinent of the FIVE drugs in its pipeline will be the phase 2 results of erivedge on operable BCC, which will be revealed early in 2014. I am optimistic about these results in the same way that I stated I was optimistic about the EU results on here earlier this year. I took some flack for stating that CRIS was going to be at 5 dollars before long. I still stand by that. It got up to $4.50 post EU approval. I believe that the operable BCC results will be positive and that this death in the phase 1 trial will be shown to be unrelated to CUDC-427. Did it dawn on any of the people who yanked their money out of CRIS as they panicked that the one person who died was not only 1 month removed from treatment when they did but had stage 4 breast cancer which had metastasized to the lungs, bone, ovaries AND liver?? Or did these people not even bother to read this far? So, in other words, CUDC-427 simply did not save this advanced cancer patient. On the surface there certainly seems to be no reason to believe that CUDC-427 in any way caused or even contributed to this one person's liver failure as opposed to the failure being a direct result of the highly metastasized cancer that had spread to and beyond her liver.
Wow on top of being a rude #$%$ you are also clearly incompetent. Pretty obvious that he was being sarcastic and eluding to the fact that this one drug is only one of many things that Curis has in its pipeline, the most significant right now being its operable BCC results which should be out in early 2014.
This company doesn't suffer from a lack of potential, and it has a nice cash cow with erivedge, a drug that fills a unique niche in the industry. It's all the weak hands and poor share holder loyalty that hurts it.
Mmm...no. I don't advise that you wait for the market to pop back up before you buy back in. However the market is predictably and soundly down today and the volatility index is up 10 percent right now, which is exactly what I expect to continue until the debt ceiling is raised. The closer we get to the 17th, the more volatile it will get. When the ceiling is raised and things stabilize some I will be buying back in.
I will say that I think it's a sound idea to derisk by getting out of equities this week until our elected clowns raise the debt ceiling. Boehner has said he won't let a default happen, but as we get closer to the 17th I expect investors to become increasingly nervous.
You seem to forget that the biopharm market operates largely independently from the broader market. Don't let Obozo scare you with his antics. And even if there is a correction in the next 8 months that does affect the stock (which I don't believe there will be), you'd rather save 10 percent and risk losing 55? Cempra has gone up nearly 40% in the past 4 weeks alone. My 2 cents.
DRTX is also intriguing and undervalued IMO, however it's scope is more limited. Solithromycin has shown to not only be powerfully effective at treating MRSA infections, but it is available in both PO and IV formulations. You can also probably tack on an additional 1 to 200 million a year of earnings potential for cempras other product in development, taksta.
Yes, dickierzphazlitt. It should be further noted that peak earnings for telithromycin were expected to be 1.5 billion prior to the side effects, and also that these same side effects of liver toxicity were not at all present in cempra's phase 2 trial. I too believe that Solithromycin has the same earnings potential that telithromycin once had. With a comparative market cap of JUST 400 million I consider cempra to be a prime buy-and-hold stock.
At what point will they be filing a new drug application with the fda for solithromycin do you think? Late 2014?
You know, when the stock was over 10 bucks and he DARED to challenge your notion that Arena wasn't the BEST buy for the rest of 2012??? How do you #$%$ who slammed him look now? Hahahahahahaha!!!!!!!!!!!!